检索规则说明:AND代表“并且”;OR代表“或者”;NOT代表“不包含”;(注意必须大写,运算符两边需空一格)
检 索 范 例 :范例一: (K=图书馆学 OR K=情报学) AND A=范并思 范例二:J=计算机应用与软件 AND (U=C++ OR U=Basic) NOT M=Visual
作 者:李廷[1] 叶雯霞 赖小英[1] 周丽妙 施勇[1]
机构地区:[1]浙江省丽水市人民医院肿瘤内科,浙江丽水323000
出 处:《中国现代医生》2015年第36期66-68,共3页China Modern Doctor
基 金:浙江省医药卫生科技计划项目(2013KYB299)
摘 要:目的 观察卵巢癌术后双途径化疗和静脉化疗对CA125半衰期的影响。方法 2006年5月-2015年5月收集我院65例卵巢癌术后患者,根据术后一般情况、经济条件和患者意愿,随机分为观察组35例和对照组30例,观察组行双途径化疗,对照组行单纯静脉化疗,比较两种化疗方式对CA125半衰期的影响以及两种化疗方式的不良反应。结果 观察组中,CA125的半衰期为(15.86±2.52)d;对照组中,CA125的半衰期为(26.08±3.07)d,两组差异有统计学意义(P〈0.05);两组的血液学毒副反应和非血液学毒副反应比较差异无统计学意义(P〉0.05)。结论 卵巢癌术后双途径化疗可以缩短CA125的半衰期,不良反应和单纯静脉化疗相当,对延长患者生存时间可能有益,值得临床进一步推广应用。Objective To observe the effect of dual route chemotherapy and intravenous chemotherapy on the half-life of CA125 after ovarian cancer surgery.Methods Clinical data of 65 cases of ovarian cancer patients in our hospital from May 2006 to May 2015 were selected,according to the general situation,economic conditions and patients will,they were randomly divided into observation group with 35 cases and control group with 30 cases,the observation group was treated with dual route chemotherapy,and the control group was treated with intravenous chemotherapy,the effect of two kinds of chemotherapy on CA125 half life,and the adverse reactions of two kinds of chemotherapy were compared.Results The half-life of CA125 was(15.86±2.52) days in the observation group,and(26.08±3.07) days in the control group.The difference between the two groups was statistically significant(P〈0.05).There was no significant difference between the two groups in hematological toxicity and non hematological toxicity(P〉0.05).Conclusion The dual route chemotherapy after ovarian cancer surgery can shorten the half-life of CA125,and adverse reactions is similar with simple intravenous chemotherapy,which may be useful for prolonging the survival time of patients and is worth to further promote the clinical application.
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在链接到云南高校图书馆文献保障联盟下载...
云南高校图书馆联盟文献共享服务平台 版权所有©
您的IP:216.73.216.7